A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

ClinicalTrials.gov ID

NCT07633470

Lead Sponsor

Alpha Cognition, IncINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

150Estimated

Last Update Posted

Aug 28, 2026Actual

Start Date

May 20, 2026Actual

Primary Completion Date

Apr 2027Estimated

Completion Date

Apr 2027Estimated

Official Title

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

Brief Summary

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

• Alzheimer Disease

• Zunveyl®

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Male and female outpatients aged 50 years and greater at the time of informed consent.

2. Diagnosis of probable Alzheimer's disease in accordance with the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, supported by biomarker confirmation using the Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test.

3. Cognitive impairment consistent with mild-to-moderate Alzheimer's disease, confirmed at Screening by the Saint Louis University Mental Status (SLUMS) examination, with scores meeting the following criteria based on education level:

   1. Less than high school education: SLUMS score 10 -18
   2. High school education or higher: SLUMS score 10 - 20

4. The participant must be capable of providing informed consent; if not, a legally authorized representative (LAR)/caregiver may provide consent in compliance with federal and Institutional Review Board (IRB) regulations.

5. Participant currently receiving non-exclusionary chronic medications are eligible, provided doses have been stable for greater than or equal to [>=] 4 weeks.

6. Any recent medication changes at baseline (less than 8 weeks) should be reviewed to confirm they are not expected to confound efficacy or safety assessments.

7. Availability of a reliable full-time caregiver or study partner who serves as a knowledgeable informant and:

   1. Has at least 20 hours per week of direct contact with the participant;
   2. Is capable of consistently completing tolerability assessments and the Neuropsychiatric Inventory (NPI) across study visits;
   3. Can observe and accurately report tolerability, neuropsychiatric symptoms (including sleep), and caregiver distress;
   4. Is available and willing to participate in all required study visits and assessments.

8. Participants must not have received disallowed concomitant medications within 2 weeks or 5 half-lives (whichever is longer) prior to baseline.

9. Compliance with washouts will be confirmed by medication history review.

10. The participant and caregiver must be willing and able to comply with all study procedures, including visits, assessments, and follow-up in an outpatient setting.

Exclusion Criteria:

1. Dementia due to causes other than Alzheimer's disease, including but not limited to vascular dementia, frontotemporal dementia, or substance/medication-induced dementia, Parkinson's disease dementia and Lewy body dementia, Huntington's dementia, or any other types.

2. Negative biomarkers result on the Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, indicating lack of biomarker support for a diagnosis of probable Alzheimer's disease according to the 2024 NIA-AA criteria.

3. Hospitalization in a psychiatric or mental health facility (For example [e.g.], psychiatric hospital, inpatient ward) at screening or within 3 months prior to screening.

4. Any concurrent or unstable medical condition that, in the investigator's judgment, could interfere with study conduct, confound interpretation of study data, or pose an undue risk to the participant's safety. Includes but is not limited to:

   1. Malignancy within the past 2 years, except for adequately treated non-melanotic skin cancer, localized prostate cancer or cervical cancer in situ (other non-metastatic malignancies may be allowed with medical monitor approval).
   2. Hematologic, endocrine, metabolic, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disorders that are unstable or progressive.
   3. Cardiovascular examples: three documented episodes of blood pressure greater than (>)185/100 millimeters of mercury (mmHg), unstable ischemic heart disease, dilated cardiomyopathy, unstable valvular disease, cardiac conduction abnormalities, or bradycardia (participants will be excluded if resting (awake) heart rate (HR) less than (<) 50 beats per minute (bpm) confirmed on repeat, or any symptomatic bradycardia.

5. Current active clinical diagnosis of delirium, psychosis or psychotic disorder, per Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria.

6. Active major depression requiring initiation or recent change of antidepressant therapy within 2 months prior to Screening.

7. Active symptoms of diarrhea, nausea, vomiting, or abdominal pain/discomfort or any Gastrointestinal (GI) condition that may impact IP absorption, e.g. gastric bypass surgery during screening or scheduled or prn medications to treat these conditions (e.g., loperamide, ondansetron, antispasmodic drugs).

8. History of seizure disorder, anorexia nervosa, or bulimia.

9. Acute delirium at baseline (e.g., positive Confusion Assessment Method [CAM]) that has not been resolved prior to enrollment.

10. Known hypersensitivity or contraindication to Zunveyl® or galantamine-containing products.

11. Use of an investigational drug or device for neuropsychiatric symptoms within 30 days or 5 half-lives, whichever is longer prior to Baseline.

12. Life expectancy <12 months, or a hospice/palliative plan of care inconsistent with study participation.

13. Any medical, neurological, or psychiatric condition that, in the investigator's judgment, may place the participant at risk, interfere with assessments, or compromise study participation.

14. Any participant currently receiving or who has ever received Zunveyl®.

15. Weight loss of >10 in the 6-month period prior to screening.

16. Any planned general surgery during the duration of the study.

17. History of Stevens-Johnson Syndrome (TENS).

18. Significantly abnormal labs including Estimated Glomerular Filtration Rate (eGFR) <10 or Liver function Tests (LFTs) >2*Upper Limit of Normal (ULN).

19. Concomitant medications that cannot be stopped including strong Cytochrome P450 (CYP) inhibitors/inducers of 3A4 or 2D6 or a high anticholinergic burden defined as an Anticholinergic Cognitive Burden (ACB) score > 3 within 28 days prior to baseline. Any new neuropsychiatric medication that would need to be initiated during the study.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Alpha Cognition, IncINDUSTRY

jegamez@galizresearch.com305-820-3381

subhash.reddy@nexgenresearch.com419-516-0954

artaca@hotmail.com314-997-5208

tarnold@neuroclinic.org901-866-9252

• Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

  NCT01584440

  CompletedInterventionalPhase 2Updated Nov 26, 2021
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

  NCT03518073

  CompletedInterventionalPhase 2Updated Aug 30, 2022
• Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

  NCT01282619

  Unknown statusInterventionalPhase 2Phase 3Updated Jan 25, 2011
• Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease

  NCT00423228

  CompletedInterventionalNot ApplicableUpdated Jan 14, 2015
• A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

  NCT00645190

  CompletedInterventionalPhase 3Updated May 19, 2011
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

  NCT02580305

  CompletedInterventionalPhase 2Updated Jun 9, 2023